Brief communication: comparison of changes in metabolic parameters following antiretrovial therapy with treatment regimens containing tenofovir alafenamide and tenofovir disoproxil fumarate
Open Access
- 15 March 2025
- journal article
- research article
- Published by Springer Nature in AIDS Research and Therapy
- Vol. 22 (1) , 1-4
Abstract
Concerns of increased metabolic dysfunction have been heightened for HIV patients on long-term antiretroviral therapy (ART). Among first-line ART agents, Tenofovir alafenamide (TAF) may entail a marked increase in weight compared to Tenofovir disoproxil fumarate (TDF). We retrospectively evaluated changes in weight and glucose regulation among 153 treament-naïve patients. Weight-gain was more pronounced after one year of treatment with TAF versus TDF (3.5 kg versus − 1 kg, P-value < 0.001). However, weight-gain was attenuated with longer follow-up, and no increase in glucose dysregulation was noted for TAF treatment. Attribution of increased metabolic risk to treatment with TAF remains questionable.Keywords
This publication has 20 references indexed in Scilit:
- Effect of 2 Forms of Tenofovir on Duodenal Enterocytes—A Hypothesis for Different Effect of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide on Body Weight and Plasma LipidsClinical Infectious Diseases, 2024
- Switching from Tenofovir Disoproxil to Tenofovir Alafenamide Fumarate: Impact on Cardiovascular Risk and Lipid Profile in People Living with HIV, an Observational StudyAIDS Research and Human Retroviruses, 2023
- Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United StatesAIDS Research and Human Retroviruses, 2021
- Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical TrialsClinical Infectious Diseases, 2021
- Weight gain before and after switch from TDF to TAF in a U.S. cohort studyJournal of the International AIDS Society, 2021
- Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment EraJAIDS Journal of Acquired Immune Deficiency Syndromes, 2021
- Atherosclerotic Cardiovascular Disease Risk Profile of Tenofovir Alafenamide Versus Tenofovir Disoproxil FumarateOpen Forum Infectious Diseases, 2019
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical TrialsClinical Infectious Diseases, 2019
- Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?Journal of Virus Eradication, 2018
- Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017